Initiation of coverage
A broader pipeline, stronger equity story - reinitiating coverage
Klas Palin
2026-10-02
07:03 CEST
We reinitiate coverage of Medivir with a fair value range of SEK3.6–4.6 per share. Medivir is a mid-stage clinical biotechnology company. Following a transformational year, characterised by a strengthened ownership base, an expanded pipeline and an improved financial position, we believe the equity story has become both stronger and less reliant on any single asset. Over the next 18 months, we expect meaningful news flow, with several key catalysts that could materially de-risk the portfolio and support further value creation.
Funded through key clinical milestones. At the core of the company’s transformation over the past year is a strengthened shareholder base, which has enabled a significant expansion of the development portfolio while improving financial resilience. Following this summer’s equity raise, advised by DNB Carnegie, we estimate that Medivir’s current cash position is sufficient to fund operations into at least 2029.
A growing portfolio. Medivir currently has three active mid-stage development programmes: the wholly owned assets fostrox and MIV-711, together with VBX-1000, which is licensed to Vetbiolix. The portfolio spans oncology, rare diseases and veterinary medicine. All three programmes target areas of significant unmet medical need and, based on our assumptions, represent sizeable commercial opportunities if approved.
Well-received transition. YTD, Medivir has been one of the strongest-performing stocks on the Swedish market. However, the share price performance should be viewed in the context of the company’s extremely depressed valuation at the end of 2025. We reinitiate coverage with a fair value range of SEK3.6-4.6 per share and believe the company is entering a period of catalyst-rich news flow that could further de-risk the portfolio and support valuation. As a near-term catalyst, we expect topline data from the VBX-1000 study in Q4 2026. The principal risks to our outlook remain clinical setbacks and delays to development timelines.